{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:31:46Z","timestamp":1788715906940,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Transthyretin (TTR) amyloidosis manifests in two distinct forms: hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt). Despite being one of the commonest manifestations in ATTRv amyloidosis, the presence of polyneuropathy has long been underestimated in ATTRwt patients. This prospective study enrolled 72 patients with ATTRv (<jats:italic>n<\/jats:italic>\u2009=\u200911) and ATTRwt (<jats:italic>n<\/jats:italic>\u2009=\u200961) amyloidosis. Our standardized protocol included a detailed patient history, clinical and electrophysiological examinations, assessment of unrelated neuropathy risk factors and predefined red flags for ATTRv amyloidosis, as well as serum neurofilament light chain concentrations (NfL). We found signs of polyneuropathy in all ATTRv patients and a vast majority of ATTRwt patients (84%). Predefined red flag symptom clusters were prevalent in both subgroups, indicating significant overlap, however gastrointestinal symptoms were more frequent in ATTRv amyloidosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), while carpal tunnel syndrome was less common (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) compared to ATTRwt amyloidosis. The groups differed in severity of polyneuropathy, with ATTRv patients demonstrating more pronounced subjective limitations, greater clinical disability, marked nerve conduction abnormalities, and higher serum NfL concentrations (<jats:italic>p<\/jats:italic>\u2009=\u20090.011). Our findings underscore a high prevalence of polyneuropathy in patients with transthyretin amyloidosis, irrespective of its origin. Differences in the severity of polyneuropathy as well as in red flags indicate different underlying mechanisms of damage.<\/jats:p>","DOI":"10.1038\/s41598-025-21745-5","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:40:25Z","timestamp":1759866025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags"],"prefix":"10.1038","volume":"15","author":[{"given":"Janna M.","family":"Siemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"H\u00e4nselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke L.","family":"Sassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominica","family":"Ratuszny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Seeliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike F.","family":"Dohrn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vega","family":"G\u00f6decke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Bavendiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5695","authenticated-orcid":false,"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"21745_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima, Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J. Neurol. Neurosurg. Psychiatry. 86, 1036\u20131043 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"21745_CR2","doi-asserted-by":"publisher","unstructured":"Ando, Y. et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 29, 143\u2013155 (2022). https:\/\/doi.org\/10.1080\/13506129.2022.2052838. Preprint","DOI":"10.1080\/13506129.2022.2052838"},{"key":"21745_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho, T., Maurer, M. S. & Suhr, O. B. THAOS-The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr. Med. Res. Opin. 29, 63\u201376 (2013).","journal-title":"Curr. Med. Res. Opin."},{"key":"21745_CR4","doi-asserted-by":"crossref","unstructured":"Buxbaum, J. N. Oligonucleotide drugs for transthyretin amyloidosis. N Engl. J. Med 379, 82\u201385 (2018).","DOI":"10.1056\/NEJMe1805499"},{"key":"21745_CR5","doi-asserted-by":"publisher","unstructured":"Obi, C. A., Mostertz, W. C., Griffin, J. M. & Judge, D. P. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist DeBakey Cardiovasc. J.. 18, 17\u201326 Preprint at. https:\/\/doi.org\/10.14797\/mdcvj.1066 (2022).","DOI":"10.14797\/mdcvj.1066"},{"key":"21745_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve, V. & Said, G. Familial amyloid polyneuropathy. Lancet Neurol. 10, 1086\u20131097 (2011).","journal-title":"Lancet Neurol."},{"key":"21745_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"H Koike","year":"2002","unstructured":"Koike, H. & Type, I. Transthyretin Met30) Familial amyloid polyneuropathy in Japan. Arch. Neurol. 59, 1771 (2002).","journal-title":"Arch. Neurol."},{"key":"21745_CR8","doi-asserted-by":"publisher","unstructured":"Concei\u00e7\u00e3o, I. et al. Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy. J. Peripheral Nervous Syst. 21, 5\u20139 Preprint at https:\/\/doi.org\/10.1111\/jns.12153 (2016).","DOI":"10.1111\/jns.12153"},{"key":"21745_CR9","doi-asserted-by":"publisher","unstructured":"Gonzalez-Duarte, A. & Ulloa-Aguirre, A. A brief journey through protein misfolding in transthyretin amyloidosis (Attr amyloidosis). Int. J. Mol. Sci. 22 Preprint at https:\/\/doi.org\/10.3390\/ijms222313158  (2021).","DOI":"10.3390\/ijms222313158"},{"key":"21745_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/13506129.2021.2014448","volume":"29","author":"F Kleefeld","year":"2022","unstructured":"Kleefeld, F. et al. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Amyloid 29, 92\u2013101 (2022).","journal-title":"Amyloid"},{"key":"21745_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/13506129.2021.1976751","volume":"29","author":"A Papagianni","year":"2022","unstructured":"Papagianni, A. et al. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid 29, 14\u201322 (2022).","journal-title":"Amyloid"},{"key":"21745_CR12","doi-asserted-by":"publisher","unstructured":"Yilmaz, A. et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin. Res. Cardiol. 110, 479\u2013506 Preprint at https:\/\/doi.org\/10.1007\/s00392-020-01799-3 (2021).","DOI":"10.1007\/s00392-020-01799-3"},{"key":"21745_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes, S. I. et al. Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76, 337\u2013345 (2011).","journal-title":"Neurology"},{"key":"21745_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaneurol.2020.0781","volume":"77","author":"JA Allen","year":"2020","unstructured":"Allen, J. A., Merkies, I. S. J. & Lewis, R. A. Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care. JAMA Neurol. 77, 1159 (2020).","journal-title":"JAMA Neurol."},{"key":"21745_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P., Van Der Mech\u00e9, F. G. A. & Schmitz, P. I. M. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve. 14, 1103\u20131109 (1991).","journal-title":"Muscle Nerve"},{"key":"21745_CR16","unstructured":"Coutinho, P. & L. L. J., M. S. A. R. B. A. Forty years of experience with type I amyloid neuropathy: review of 483 cases In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and Amyloidosis. 88\u201393 (1980)."},{"key":"21745_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando, Y. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J. Rare Dis. 8, 31 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"21745_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/1545968310397204","volume":"25","author":"R Phan-Ba","year":"2011","unstructured":"Phan-Ba, R. et al. Comparison of the timed 25-Foot and the 100-Meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair. 25, 672\u2013679 (2011).","journal-title":"Neurorehabil Neural Repair."},{"key":"21745_CR19","first-page":"213","volume":"52","author":"E St\u00e5lberg","year":"1999","unstructured":"St\u00e5lberg, E. et al. Standards for quantification of EMG and neurography. The international federation of clinical neurophysiology. Electroencephalogr. Clin. Neurophysiol. Suppl. 52, 213\u2013220 (1999).","journal-title":"Electroencephalogr. Clin. Neurophysiol. Suppl."},{"key":"21745_CR20","unstructured":"Christian Bischoff (Herausgeber) & R. D. (Herausgeber). EMG NLG: Elektromyografie - Nervenleitungsuntersuchungen Gebundene Ausgabe \u2013\u200922. vol. 22 (2018)."},{"key":"21745_CR21","doi-asserted-by":"crossref","unstructured":"Taams, N. E., Drenthen, J., Hanewinckel, R., Ikram, M. A. & van Doorn, P. A. Age-Related Changes in Neurologic Examination and Sensory Nerve Amplitude in the General Population. Neurology 101, e1351\u2013e1358 (2023).","DOI":"10.1212\/WNL.0000000000207665"},{"key":"21745_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","volume":"15","author":"J Solignac","year":"2022","unstructured":"Solignac, J. et al. Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. Clin. Kidney J. 15, 1747\u20131754 (2022).","journal-title":"Clin. Kidney J."},{"key":"21745_CR23","doi-asserted-by":"crossref","unstructured":"Ferraro, P. M. et al. Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci 11, 980 (2021).","DOI":"10.3390\/brainsci11080980"},{"key":"21745_CR24","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"21745_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jhsa.2009.11.003","volume":"35","author":"KD Bickel","year":"2010","unstructured":"Bickel, K. D. Carpal tunnel syndrome. J. Hand Surg. Am. 35, 147\u2013152 (2010).","journal-title":"J. Hand Surg. Am."},{"key":"21745_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","volume":"44","author":"JP Donnelly","year":"2019","unstructured":"Donnelly, J. P., Hanna, M., Sperry, B. W. & Seitz, W. H. Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis. J. Hand Surg. Am. 44, 868\u2013876 (2019).","journal-title":"J. Hand Surg. Am."},{"key":"21745_CR27","doi-asserted-by":"publisher","unstructured":"Gertz, M. A., Mauermann, M. L., Grogan, M. & Coelho, T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav. 9 Preprint at  https:\/\/doi.org\/10.1002\/brb3.1371 (2019).","DOI":"10.1002\/brb3.1371"},{"key":"21745_CR28","doi-asserted-by":"publisher","unstructured":"Carroll, A. et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J. Neurol. Neurosurg. Psychiatry. 93, 668\u2013678 Preprint at https:\/\/doi.org\/10.1136\/jnnp-2021-327909  (2022).","DOI":"10.1136\/jnnp-2021-327909"},{"key":"21745_CR29","doi-asserted-by":"publisher","unstructured":"\u017divkovi\u0107, S., Soman, P. & Lacomis, D. Late-onset peripheral neuropathy in patients with wild type transthyretin amyloidosis (wtATTR). Amyloid. 27, 142\u2013143 Preprint at  https:\/\/doi.org\/10.1080\/13506129.2019.1697224 (2020).","DOI":"10.1080\/13506129.2019.1697224"},{"key":"21745_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jns.12403","volume":"25","author":"F Wajnsztajn Yungher","year":"2020","unstructured":"Wajnsztajn Yungher, F. et al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J. Peripheral Nerv. Syst. 25, 265\u2013272 (2020).","journal-title":"J. Peripheral Nerv. Syst."},{"key":"21745_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors, L. H. et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin. Circulation 133, 282\u2013290 (2016).","journal-title":"Circulation"},{"key":"21745_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt, H. H. et al. Estimating the global prevalence of transthyretin Familial amyloid polyneuropathy. Muscle Nerve. 57, 829\u2013837 (2018).","journal-title":"Muscle Nerve"},{"key":"21745_CR33","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","volume":"87","author":"R Hanewinckel","year":"2016","unstructured":"Hanewinckel, R. et al. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 87, 1892\u20131898 (2016).","journal-title":"Neurology"},{"key":"21745_CR34","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/acn3.51924","volume":"10","author":"S Pinton","year":"2023","unstructured":"Pinton, S. et al. Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy. Ann. Clin. Transl Neurol. 10, 2347\u20132359 (2023).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"21745_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/jnnp-2023-332180","volume":"95","author":"D Beauvais","year":"2024","unstructured":"Beauvais, D. et al. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers. J. Neurol. Neurosurg. Psychiatry. 95, 489\u2013499 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"21745_CR36","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/acn3.51636","volume":"9","author":"R Freeman","year":"2022","unstructured":"Freeman, R. et al. Cutaneous amyloid is a biomarker in early\u2009<\u2009scp\u2009>\u2009ATTRv neuropathy and progresses across disease stages. Ann. Clin. Transl Neurol. 9, 1370\u20131383 (2022).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"21745_CR37","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.3390\/biomedicines10123226","volume":"10","author":"F Perfetto","year":"2022","unstructured":"Perfetto, F. et al. Transthyretin cardiac amyloidosis: a Cardio-Orthopedic disease. Biomedicines 10, 3226 (2022).","journal-title":"Biomedicines"},{"key":"21745_CR38","doi-asserted-by":"publisher","unstructured":"Petros, F. E. et al. Gait abnormalities in older adults with transthyretin cardiac amyloidosis. Amyloid. https:\/\/doi.org\/10.1080\/13506129.2024.2319133 (2024).","DOI":"10.1080\/13506129.2024.2319133"},{"key":"21745_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/joim.13222","volume":"289","author":"P Eldhagen","year":"2021","unstructured":"Eldhagen, P. et al. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J. Intern. Med. 289, 895\u2013905 (2021).","journal-title":"J. Intern. Med."},{"key":"21745_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor, M. et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripheral Nerv. Syst. 24, 314\u2013319 (2019).","journal-title":"J. Peripheral Nerv. Syst."},{"key":"21745_CR41","doi-asserted-by":"publisher","first-page":"E412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary Transthyretin-Mediated amyloidosis. Neurology 96, E412\u2013E422 (2021).","journal-title":"Neurology"},{"key":"21745_CR42","doi-asserted-by":"publisher","unstructured":"Rossor, A. M. & Reilly, M. M. Blood biomarkers of peripheral neuropathy. Acta Neurologica Scandinavica. 146, 325\u2013331 Preprint at. https:\/\/doi.org\/10.1111\/ane.13650  (2022).","DOI":"10.1111\/ane.13650"},{"key":"21745_CR43","doi-asserted-by":"publisher","unstructured":"Hood, C. J. et al. Update on disease-specific biomarkers in Transthyretin Cardiac Amyloidosis. Current Heart Failure Reports. 19, 356\u2013363 Preprint at  https:\/\/doi.org\/10.1007\/s11897-022-00570-1 (2022).","DOI":"10.1007\/s11897-022-00570-1"},{"key":"21745_CR44","doi-asserted-by":"publisher","first-page":"10111","DOI":"10.1038\/s41598-024-60025-6","volume":"14","author":"HF Pernice","year":"2024","unstructured":"Pernice, H. F. et al. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis. Sci. Rep. 14, 10111 (2024).","journal-title":"Sci. Rep."},{"key":"21745_CR45","doi-asserted-by":"publisher","unstructured":"Yamamoto, H. & Yokochi, T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 6, 1128\u20131139 Preprint at. https:\/\/doi.org\/10.1002\/ehf2.12518  (2019).","DOI":"10.1002\/ehf2.12518"},{"key":"21745_CR46","doi-asserted-by":"publisher","unstructured":"Witteles, R. M. et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC: Heart Failure. 7, 709\u2013716 Preprint at https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010  (2019).","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"21745_CR47","doi-asserted-by":"publisher","unstructured":"Nativi-Nicolau, J. N., Karam, C., Khella, S. & Maurer, M. S. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews. 27, 785\u2013793 Preprint at. https:\/\/doi.org\/10.1007\/s10741-021-10080-2  (2022).","DOI":"10.1007\/s10741-021-10080-2"},{"key":"21745_CR48","doi-asserted-by":"crossref","unstructured":"Poli, L. et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol 14, 1242815 (2023).","DOI":"10.3389\/fneur.2023.1242815"},{"key":"21745_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike, H. & Katsuno, M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol. Ther. 9, 317\u2013333 (2020).","journal-title":"Neurol. Ther."},{"key":"21745_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ejhf.2823","volume":"25","author":"G Tini","year":"2023","unstructured":"Tini, G. et al. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study. Eur. J. Heart Fail. 25, 845\u2013853 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"21745_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000522370","volume":"146","author":"R Fenoglio","year":"2022","unstructured":"Fenoglio, R. et al. Renal involvement in transthyretin amyloidosis: the double presentation of transthyretin amyloidosis deposition disease. Nephron 146, 481\u2013488 (2022).","journal-title":"Nephron"},{"key":"21745_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","volume":"120","author":"E Selvin","year":"2007","unstructured":"Selvin, E., Burnett, A. L. & Platz, E. A. Prevalence and risk factors for erectile dysfunction in the US. Am. J. Med. 120, 151\u2013157 (2007).","journal-title":"Am. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21745-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:40:27Z","timestamp":1759866027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21745"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21745-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35028"}}